Literature DB >> 26100256

Can Good Infection Control Be Obtained in One-stage Exchange of the Infected TKA to a Rotating Hinge Design? 10-year Results.

Akos Zahar1, Daniel O Kendoff2, Till O Klatte3, Thorsten A Gehrke2.   

Abstract

BACKGROUND: Prosthetic joint infection (PJI) occurs in 1% to 2% of total knee arthroplasties (TKAs). Although two-stage exchange is the preferred management method of patients with chronic PJI in TKA in North America, one-stage exchange is an alternative treatment method, but long-term studies of this approach have not been conducted. QUESTIONS/PURPOSES: We reviewed our minimum 9-year results of 70 patients who underwent one-stage exchange arthroplasty with a rotating hinge design to determine: (1) What was the proportion of patients free of infection? (2) What was the patient rate of survival free of any reoperation? (3) What were the clinical outcomes as measured by Hospital for Special Surgery scores? (4) What proportion of patients developed radiographic evidence of loosening?
METHODS: All one-stage revision TKAs for infection between January 1 and December 31, 2002, with a minimum 9-year followup (mean, 10 years; range, 9-11 years), in which patients had been seen within the last 1 year, were included in this retrospective review. During that period, 11 patients with infected TKAs were treated with other approaches (including two-stage approaches in eight); the general indication for one-stage revision was the diagnosis of PJI with a known causative organism. Exclusion criteria were culture-negative preoperative aspiration, known allergy to local antibiotics or bone cement, or cases in which radical débridement was impossible as a result of the involvement of important anatomical structures. Eighty-one patients with PJI were seen during this period; 70 underwent one-stage exchange using our strict protocol and were reimplanted with a rotating hinge TKA. Eleven patients (15.7%) were lost to followup. Hospital for Special Surgery scores were recorded and all radiographs were evaluated for prosthetic loosening. Failure was defined as revision surgery for infection or any other cause.
RESULTS: Our 10-year infection-free survival was 93% (mean, 4.1; 95% confidence interval [CI], 89%-96%; p < 0.007); and the patient 10-year survival rate free of revision for other causes was 91% (mean, 5.2; 95% CI, 86%-95%; p < 0.002). Mean Hospital for Special Surgery knee score at last followup was 69.6 (± 22.5 SD; range, 22-100) and the mean improvement in Hospital for Special Surgery knee score from preoperative to most recent followup was 35 (± 24.2 SD; range, 13-99). Evidence of radiographic loosening was seen in 11 patients at last followup, whereby in six patients, there was need for revision surgery.
CONCLUSIONS: Our study results showed an overall infection control rate of 93% and good clinical results using our one-stage approach, which combines aggressive débridement of the collateral ligaments and posterior capsule with a rotating hinge implant. These results are comparable with two-stage techniques at a followup of 10 years; further research into one-stage exchange techniques for PJI in TKA appears warranted. LEVEL OF EVIDENCE: Level IV, therapeutic study.

Entities:  

Mesh:

Year:  2016        PMID: 26100256      PMCID: PMC4686525          DOI: 10.1007/s11999-015-4408-5

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  44 in total

1.  [One-stage reimplantation for the salvage of total knee arthroplasty complicated by infection].

Authors:  H Lu; B Kou; J Lin
Journal:  Zhonghua Wai Ke Za Zhi       Date:  1997-08

Review 2.  Prosthetic-joint infections.

Authors:  Werner Zimmerli; Andrej Trampuz; Peter E Ochsner
Journal:  N Engl J Med       Date:  2004-10-14       Impact factor: 91.245

3.  One-stage reimplantation for infected total knee arthroplasty.

Authors:  S B Göksan; M A Freeman
Journal:  J Bone Joint Surg Br       Date:  1992-01

4.  [Mid- to long-term results after treatment of 118 cases of periprosthetic infections after knee joint replacement using one-stage exchange surgery].

Authors:  G von Foerster; D Klüber; U Käbler
Journal:  Orthopade       Date:  1991-06       Impact factor: 1.087

5.  Duo-condylar total knee arthroplasty.

Authors:  C S Ranawat; J J Shine
Journal:  Clin Orthop Relat Res       Date:  1973 Jul-Aug       Impact factor: 4.176

6.  The management of infected total knee replacements.

Authors:  M A Freeman; R A Sudlow; M W Casewell; S S Radcliff
Journal:  J Bone Joint Surg Br       Date:  1985-11

7.  Results of direct exchange or debridement of the infected total knee arthroplasty.

Authors:  Mauricio Silva; Ravi Tharani; Thomas P Schmalzried
Journal:  Clin Orthop Relat Res       Date:  2002-11       Impact factor: 4.176

8.  Comparison of a static with a mobile spacer in total knee infection.

Authors:  Roger H Emerson; Michael Muncie; Tiffera R Tarbox; Linda L Higgins
Journal:  Clin Orthop Relat Res       Date:  2002-11       Impact factor: 4.176

9.  Primary exchange revision arthroplasty for infected total knee replacement: a long-term study.

Authors:  Frederick F Buechel; Frank P Femino; Jerry D'Alessio
Journal:  Am J Orthop (Belle Mead NJ)       Date:  2004-04

10.  Is single-stage revision according to a strict protocol effective in treatment of chronic knee arthroplasty infections?

Authors:  Fares Sami Haddad; Mohamed Sukeik; Sulaiman Alazzawi
Journal:  Clin Orthop Relat Res       Date:  2015-01       Impact factor: 4.176

View more
  19 in total

1.  Short-interval two-stage approach to primary total knee arthroplasty for acutely septic osteoarthritic knees.

Authors:  Bettina Hochreiter; Carol Strahm; Henrik Behrend
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2016-01-14       Impact factor: 4.342

2.  CORR Insights®: What are the Factors Associated With Re-revision After One-stage Revision for Periprosthetic Joint Infection of the Hip? A Case-control Study.

Authors:  Hany Bedair
Journal:  Clin Orthop Relat Res       Date:  2019-10       Impact factor: 4.176

Review 3.  Implantable antimicrobial biomaterials for local drug delivery in bone infection models.

Authors:  Jeremy D Caplin; Andrés J García
Journal:  Acta Biomater       Date:  2019-01-14       Impact factor: 8.947

4.  CORR Insights®: What Is the Mid-term Survivorship of Infected Rotating-hinge Implants Treated with One-stage-exchange?

Authors:  José Cordero-Ampuero
Journal:  Clin Orthop Relat Res       Date:  2021-12-01       Impact factor: 4.755

Review 5.  Management of prosthetic joint infections: a guidelines comparison.

Authors:  M Ometti; E Delmastro; V Salini
Journal:  Musculoskelet Surg       Date:  2022-01-06

Review 6.  Current Options and Emerging Biomaterials for Periprosthetic Joint Infection.

Authors:  Ashley E Levack; Erika L Cyphert; Mathias P Bostrom; Christopher J Hernandez; Horst A von Recum; Alberto V Carli
Journal:  Curr Rheumatol Rep       Date:  2018-04-30       Impact factor: 4.592

7.  Treatment options in PJI - is two-stage still gold standard?

Authors:  Igor Lazic; Christian Scheele; Florian Pohlig; Rüdiger von Eisenhart-Rothe; Christian Suren
Journal:  J Orthop       Date:  2021-01-20

8.  Survival analysis of one-stage exchange of infected unicompartmental knee arthroplasty: a single-center study with minimum 3 years follow-up.

Authors:  Hakan Kocaoğlu; Fabian Hennes; Hussein Abdelaziz; Michael E Neufeld; Thorsten Gehrke; Mustafa Citak
Journal:  Eur J Orthop Surg Traumatol       Date:  2022-01-23

9.  What Is the Mid-term Survivorship of Infected Rotating-hinge Implants Treated with One-stage-exchange?

Authors:  Malte Ohlmeier; Fadi Alrustom; Mustafa Citak; Jochen Salber; Thorsten Gehrke; Jannik Frings
Journal:  Clin Orthop Relat Res       Date:  2021-12-01       Impact factor: 4.176

10.  Microbiology of Periprosthetic Hip and Knee Infections in Surgically Revised Cases from 34 Centers in Mainland China.

Authors:  Hui-Ming Peng; Zong-Ke Zhou; Fei Wang; Shi-Gui Yan; Peng Xu; Xi-Fu Shang; Jia Zheng; Qing-Sheng Zhu; Li Cao; Xi-Sheng Weng
Journal:  Infect Drug Resist       Date:  2021-06-25       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.